Last updated: August 2, 2026
Lodosyn is a mature branded carbidopa product used with levodopa in Parkinson’s disease. Its commercial position is structurally weak: carbidopa is available from multiple generic manufacturers, the product has no meaningful modern patent moat, and Merck does not separately report Lodosyn revenue. Demand is durable because Parkinson’s disease treatment is chronic, but most economic value in the carbidopa market accrues to low-cost generic suppliers and combination products rather than Lodosyn.
What is Lodosyn and how is it used?
Lodosyn contains carbidopa, an aromatic amino-acid decarboxylase inhibitor. It is administered with levodopa to reduce peripheral conversion of levodopa to dopamine, allowing more levodopa to reach the brain and reducing peripheral adverse effects such as nausea and vomiting.[1]
| Attribute |
Lodosyn profile |
| Active ingredient |
Carbidopa |
| Dosage form |
Oral tablet |
| Strength |
25 mg |
| U.S. regulatory application |
NDA 017555 |
| Primary use |
Adjunct to levodopa in Parkinson’s disease |
| Innovator |
Merck |
| Drug class |
Peripheral dopa-decarboxylase inhibitor |
| Biologic status |
Not a biologic |
| Biosimilar exposure |
None |
| Generic exposure |
High |
| Commercial maturity |
Legacy product |
Lodosyn is distinct from Sinemet, which combines carbidopa and levodopa in the same tablet. Lodosyn allows physicians to add carbidopa separately when adjusting the carbidopa-to-levodopa ratio or when using levodopa supplied in another formulation.
How large is the Lodosyn market?
The standalone Lodosyn market is likely small relative to the broader Parkinson’s disease drug market. Public company filings do not disclose a separate Lodosyn revenue line, prescription count, or gross margin. Merck reports pharmaceutical products at much broader portfolio levels, preventing a reliable product-level revenue calculation.[2]
The relevant commercial market has three layers:
- Generic carbidopa tablets.
- Carbidopa-levodopa combination products, including generic Sinemet equivalents.
- Branded extended-release and advanced delivery products such as Rytary, Duopa and Crexont.
Lodosyn competes primarily with generic carbidopa tablets for adjunctive use. It also competes indirectly with fixed-dose carbidopa-levodopa products that eliminate the need for a separate carbidopa prescription.
What drives demand for Lodosyn?
Demand is tied to several durable factors:
- Growth in the treated Parkinson’s disease population.
- Long-term use of levodopa therapy.
- Physician preference for titratable carbidopa dosing.
- Tolerability management during levodopa initiation or dose escalation.
- Availability and reimbursement of generic alternatives.
The product has limited ability to capture growth from the overall Parkinson’s disease market because the active ingredient is clinically interchangeable with generic carbidopa in most routine uses.
What is the financial trajectory for Lodosyn?
Lodosyn’s financial trajectory is best characterized as mature, low-growth and margin-compressed.
| Financial factor |
Expected effect on Lodosyn |
| Prescription demand |
Stable to modestly growing |
| Net price |
Downward pressure from generic competition |
| Volume share |
Low relative to generic carbidopa |
| Brand loyalty |
Limited |
| Reimbursement |
Increasingly favors generic substitution |
| Manufacturing economics |
Potentially favorable at scale, but constrained by low volume |
| Revenue disclosure |
Not separately reported by Merck |
| Long-term outlook |
Declining branded relevance |
The product can maintain recurring demand because Parkinson’s disease treatment is chronic. That demand does not translate into strong branded revenue. Pharmacy benefit managers, Medicare Part D plans and state Medicaid programs generally favor the lowest-cost therapeutically equivalent product. A legacy brand can remain available while losing most prescriptions to generics.
Lodosyn’s financial value is therefore more likely to come from residual cash generation, portfolio continuity and supply relationships than from material revenue growth. The absence of product-level disclosure means no defensible public estimate can be assigned to annual Lodosyn sales or operating profit.
When does Lodosyn lose exclusivity?
Lodosyn’s meaningful regulatory exclusivity expired decades ago. FDA records identify the product as a legacy NDA approved in the 1970s, placing it outside any modern new-drug exclusivity period.[3]
| Exclusivity category |
Lodosyn status |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
None identified |
| Pediatric exclusivity |
None currently relevant |
| Qualified infectious-disease exclusivity |
Not applicable |
| Reference-product exclusivity |
Expired |
| Patent-based exclusivity |
No material current barrier identified |
| Generic entry |
Established |
The commercial question is not when Lodosyn loses exclusivity. It already operates in a post-exclusivity market. The relevant issue is whether the branded product can retain prescriptions despite generic substitution.
What patents protect Lodosyn?
Lodosyn is not protected by a meaningful active patent estate covering the original carbidopa tablet product. The foundational composition and use patents associated with carbidopa and levodopa therapy expired long ago.
Are there formulation patents for Lodosyn?
No modern formulation patent position is publicly associated with Lodosyn’s conventional 25 mg tablet that would materially restrict generic carbidopa competition. The dosage form is technically straightforward compared with extended-release capsules, intestinal gels, inhaled products or implantable delivery systems.
Potential patent categories in the broader carbidopa-levodopa market include:
- Extended-release dissolution profiles.
- Multiparticulate capsules.
- Continuous intestinal infusion.
- Device-assisted delivery.
- Combination regimens.
- Method-of-use claims for motor fluctuation management.
Those categories generally protect competing products rather than Lodosyn itself.
Are there method-of-use patents for Lodosyn?
Lodosyn’s label covers use with levodopa in Parkinson’s disease, but the underlying therapeutic concept is longstanding. No contemporary method-of-use patent appears to create a substantial barrier to generic carbidopa tablets.
Any generic applicant could face ordinary regulatory requirements related to bioequivalence, labeling and manufacturing quality. Those requirements are regulatory hurdles, not a durable Lodosyn patent moat.
What is the FDA regulatory status of Lodosyn?
Lodosyn is an FDA-approved oral carbidopa product associated with NDA 017555.[3] Its approved role is adjunctive use with levodopa.
The regulatory profile is mature:
- The product has a long-established safety and efficacy record.
- The active ingredient is well understood.
- Generic carbidopa products can rely on the established reference-product framework.
- The main regulatory risks relate to manufacturing compliance, product availability and supply quality rather than clinical development.
Lodosyn does not face biosimilar competition because carbidopa is a small-molecule drug. Generic competition is governed through abbreviated new drug applications, not the biosimilar pathway.
What is the Orange Book status of Lodosyn?
The Orange Book is relevant for identifying reference-product status, therapeutic equivalents and listed patent or exclusivity information.[4] Lodosyn’s commercial position reflects an old reference product with established generic competition.
| Orange Book issue |
Commercial implication |
| Reference product |
Supports generic approval pathways |
| Listed patents |
No current patent barrier with material market effect identified |
| Therapeutic equivalents |
Generic substitution is central to market access |
| Exclusivity |
No meaningful remaining exclusivity |
| Paragraph IV risk |
Low strategic value because core exclusivity has expired |
The absence of a significant active patent estate reduces the likelihood that a Paragraph IV challenge would be a major event for Lodosyn. Generic applicants do not need to overcome a valuable late-life patent position to enter the market.
Which companies compete with Lodosyn?
Lodosyn competes with generic carbidopa suppliers and with branded carbidopa-levodopa products.
Generic carbidopa competitors
Generic manufacturers have included companies active in solid oral dosage products, such as:
- Amneal Pharmaceuticals.
- Alvogen.
- Zydus Pharmaceuticals.
- Teva Pharmaceuticals.
- Endo or legacy Par Pharmaceutical entities.
- Other ANDA holders and contract manufacturers.
The exact active supplier set changes over time as products are discontinued, transferred or affected by manufacturing constraints. Generic competition is normally determined by wholesaler contracts, pharmacy formularies, price and supply reliability.
Branded and differentiated competitors
| Product |
Company |
Key competitive attribute |
| Sinemet |
Merck, legacy brand |
Fixed-dose carbidopa-levodopa combination |
| Generic carbidopa-levodopa |
Multiple companies |
Low cost and broad substitution |
| Rytary |
Amneal |
Extended-release carbidopa-levodopa |
| Duopa |
AbbVie |
Intestinal gel delivered through infusion |
| Crexont |
Amneal |
Extended-release carbidopa-levodopa capsule |
| Inbrija |
Acorda |
Inhaled levodopa for intermittent OFF episodes |
These products do not all compete for the same prescription. Rytary, Duopa and Crexont address formulation, duration or motor fluctuation needs. Lodosyn remains a low-cost adjunctive tablet rather than an advanced delivery product.
What generic entry risks exist for Lodosyn?
Generic entry is already the primary market condition. The principal risks are continued share loss, price erosion and pharmacy-level substitution.
Generic launch scenarios
| Scenario |
Likely outcome |
| Stable generic supply |
Lodosyn prescriptions continue to migrate to generics |
| New low-cost entrant |
Further price compression and formulary exclusion |
| Generic shortage |
Temporary branded demand may increase |
| Manufacturing disruption |
Supply risk rises for both brand and generic products |
| Brand discontinuation |
Pharmacies shift to generic carbidopa if available |
| Formulary redesign |
Brand access narrows unless discounting offsets the price gap |
The most plausible long-term scenario is a small residual branded market supported by prescriber familiarity, patient continuity and occasional generic supply disruptions. A major branded rebound would require a material generic shortage, a supply-quality event or a commercial strategy that creates reimbursement preference. No such structural catalyst is apparent from the product’s established market position.
What patent litigation affects Lodosyn?
No major current patent litigation involving Lodosyn is central to its commercial outlook. The product’s relevant patent disputes are historical rather than an active source of market protection.
The absence of litigation has two implications:
- There is no visible patent settlement delaying generic entry.
- There is no near-term litigation event likely to restore exclusivity or materially change pricing.
Any litigation risk is more likely to arise from generic manufacturing, labeling, antitrust or supply matters than from Lodosyn composition patents.
Are there licensing deals involving Lodosyn?
No major recent licensing transaction has been publicly identified as a driver of Lodosyn’s value. The product has historically been associated with Merck and its legacy Parkinson’s disease portfolio. Product-level licensing economics are not disclosed in Merck’s public financial reporting.
A transfer of commercialization rights would probably be driven by portfolio rationalization, manufacturing efficiency or geographic distribution rather than by a patent-backed growth thesis.
How strong is the Lodosyn patent estate?
Lodosyn has a weak patent estate by current pharmaceutical standards.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
Expired |
| New formulation protection |
Limited or absent |
| Method-of-use protection |
Limited |
| Regulatory exclusivity |
Expired |
| Generic substitution resistance |
Low |
| Litigation leverage |
Low |
| Manufacturing complexity |
Low to moderate |
| Commercial defensibility |
Low |
The product’s main barriers are operational. A manufacturer must maintain FDA-compliant production, source active pharmaceutical ingredient, meet dissolution and content-uniformity specifications, and maintain reliable distribution. These barriers can cause temporary supply constraints but do not produce durable market exclusivity.
How does Lodosyn compare with Sinemet, Rytary and Crexont?
| Attribute |
Lodosyn |
Sinemet |
Rytary |
Crexont |
| Active ingredients |
Carbidopa |
Carbidopa/levodopa |
Carbidopa/levodopa |
Carbidopa/levodopa |
| Delivery |
Immediate-release tablet |
Immediate-release tablet |
Extended-release capsule |
Extended-release capsule |
| Primary role |
Separate carbidopa adjunct |
Standard levodopa replacement |
Extended symptom control |
Extended symptom control |
| Generic pressure |
High |
High |
Emerging or limited, depending on presentation |
Limited as a newer product |
| Patent value |
Low |
Legacy and limited |
Higher formulation value |
Higher formulation value |
| Pricing power |
Low |
Low to moderate |
Higher |
Higher |
| Patient segment |
Dose-adjustment and tolerability use |
Broad first-line levodopa use |
Motor fluctuation and duration needs |
Motor fluctuation and duration needs |
Lodosyn has the weakest pricing power in this comparison but remains clinically useful when separate carbidopa dosing is preferred.
What is the geographic coverage of Lodosyn?
Lodosyn’s strongest commercial relevance is in the United States, where the product is tied to the FDA-approved NDA and the U.S. generic substitution system. International carbidopa markets often use different brand names, local generic suppliers and fixed-dose levodopa combinations.
Geographic value is constrained by:
- Mature U.S. generic competition.
- Country-specific registration requirements.
- Local reimbursement policies.
- Limited differentiation between conventional carbidopa tablets.
- Reliance on regional distribution and manufacturing arrangements.
The product does not have the global pricing structure associated with a patented specialty medicine.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are meaningful enough to affect availability but insufficient to defend premium pricing. Carbidopa tablets require controlled sourcing and validated production, but they do not involve the complex biologic processes, specialized delivery devices or cold-chain logistics associated with higher-value products.
The primary operational risks are:
- Active pharmaceutical ingredient supply.
- Batch failures.
- Facility inspections and remediation.
- Packaging and labeling compliance.
- Low-volume manufacturing economics.
- Distributor willingness to carry a low-demand branded product.
These factors can create temporary market shortages. They do not materially strengthen Lodosyn’s long-term competitive position.
Key Takeaways
- Lodosyn is a legacy 25 mg carbidopa tablet used with levodopa for Parkinson’s disease.
- Its FDA application is NDA 017555, with approval dating to the 1970s.[3]
- Regulatory exclusivity and foundational patent protection have expired.
- Generic carbidopa competition is established and is the main force shaping price and volume.
- Merck does not disclose Lodosyn revenue separately, so product-level sales and profit cannot be calculated from public filings.[2]
- The financial trajectory is mature to declining for the brand, despite stable underlying demand for carbidopa therapy.
- Lodosyn has no biosimilar risk because it is a small-molecule drug.
- Paragraph IV litigation and patent settlements are not material current drivers.
- The main risks are generic substitution, price erosion, supply disruption and possible portfolio rationalization.
- Lodosyn’s remaining value is based on clinical familiarity, recurring chronic-use demand and supply continuity, not patent protection.
FAQs
Is Lodosyn still marketed in the United States?
Lodosyn remains associated with an FDA-approved carbidopa NDA, but commercial availability can vary by distributor, manufacturer and pharmacy supply conditions. Generic carbidopa is the principal substitute.
Is Lodosyn the same as carbidopa-levodopa?
No. Lodosyn contains carbidopa alone. Sinemet and generic carbidopa-levodopa products contain both carbidopa and levodopa in a single dosage form.
Can generic carbidopa replace Lodosyn?
In routine clinical use, generic carbidopa tablets are the direct competitive alternative. Substitution depends on the prescribed strength, approved product, pharmacy rules and applicable state regulations.
Does Lodosyn have an opportunity in Parkinson’s disease combination therapy?
Its opportunity is narrow. Lodosyn can support individualized carbidopa dosing, but most growth in Parkinson’s disease treatment is directed toward extended-release formulations, rescue therapies and device-assisted delivery.
What would most increase Lodosyn revenue?
A sustained shortage of generic carbidopa, a manufacturing disruption affecting competing products, or a reimbursement change favoring the brand would have the greatest potential to increase Lodosyn volume. None represents a durable patent-based growth strategy.
References
-
U.S. Food and Drug Administration. (2012). Lodosyn (carbidopa) tablets prescribing information. Merck Sharp & Dohme Corp.
-
Merck & Co., Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Lodosyn, NDA 017555. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. Center for Drug Evaluation and Research.
